The biotech blamed the miss on results for a physician-administered neurological exam.\n Cerevance’s attempt to unlock the first-line Parkinson\'s disease market has hit a snag, with solengepras performing no better than placebo in phase 2 when given to people with early, untreated symptoms. Boston-based Cerevance initially took solengepras, a GPR6 inverse agonist, into phase 2 as an adjunctive treatment to levodopa in Parkinson’s patients experiencing motor fluctuations. People

MELVILLE, N.Y., April 1, 2025 /PRNewswire/ -- Today Nikon Corporation announces the 100th anniversary of the launch of its JOICO microscope, marking the beginning of the company's current healthcare business unit. What started as a simple microscope product grew into the business' microscope division, which has evolved into the Nikon Healthcare Business Unit with greatly expanded optical scientific imaging technologies. The JOICO microscope's namesake originates from the abbreviation of Nippon K

SAN FRANCISCO, April 1, 2025 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today that it has received clearance from the US Food and Drug Administration (FDA) to initiate a global registration Phase 3 study of linperlisib versus physicians' choice of standard of care for the treatment of relapsed/refractory (R/R) peripheral T-cell lymphoma

CLEARWATER, Fla., April 1, 2025 /PRNewswire/ -- BayCare's Morton Plant Hospital in Clearwater recently completed the world's first TAV-in-TAV as part of a study called RESTORE. TAV-in-TAV is for people who have undergone a prior TAVR procedure, but the replacement valve is coming to the end of its life cycle and needs to be replaced. TAVR, an acronym for transcatheter aortic valve replacement and pronounced "tăver," is a minimally invasive heart valve replacement procedure used to treat severe a

The evidence-based guideline revision underscores the expanded use of LITT in metastatic disease MINNETONKA, Minn., April 1, 2025 /PRNewswire/ -- Monteris Medical announced today that the College of Neurological Surgeons (CNS) has issued clinical guidelines supporting the use of laser interstitial thermal therapy (LITT) for adults with progressive metastatic brain tumors, post-stereotactic radiosurgery (SRS). These evidence-based recommendations highlight minimally invasive LITT as an option fo

KIGALI, Rwanda and WALTHAM, Mass., April 1, 2025 /PRNewswire/ -- AKAGERA Medicines, Inc. is a biotech company focused on the discovery and development of novel lipid nanoparticle formulations of antibacterial drugs and mRNA vaccines to treat tuberculosis, avian flu, RSV and other infectious diseases. The company announced today that it completed the first cohort in its first-in-human phase 1 SAD/MAD study of AKG-100, which is an oxazolidinone class of antibiotic for treatment of pulmonary tuberc

Sterilizable, weldable, sealable thermoplastic elastomer tubing intended for biopharmaceutical processing applications that require low temperatures WILMINGTON, Del., April 1, 2025 /PRNewswire/ -- DuPont (NYSE:DD) today announced it has launched DuPont™ Liveo™ Pharma TPE Ultra-Low Temp Tubing, a new thermoplastic elastomer tubing designed to withstand the low temperatures required for many of today's biopharmaceutical processing applications. Sterilizable, weldable, sealable Liveo™ Pharma TPE Ul

– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Expect to initiate both trials in Q2 2025 – SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or Connect Biopharma), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today anno

Stratyx™ 250 is an innovative new bioreactor system from Culture Biosciences that accelerates bioprocess development, reduces costs and provides real-time remote control and monitoring for teams working on applications ranging from cell line development to protein expression. SOUTH SAN FRANCISCO, Calif., April 1, 2025 /PRNewswire/ -- Culture Biosciences, a leader in cloud-based biomanufacturing, announced the launch of Stratyx™ 250, the first mobile, cloud-integrated bioreactor designed to provi

The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated Interim biomarker data on track for Q2 2025 and topline results expected Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact o